Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil for Residual Excessive Daytime Sleepiness in Moderate to Severe Obstructive Sleep Apnea with Suboptimal CPAP Use
TCTR20210218005Phase 3Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of armodafinil in obstructive sleep apnea hypopnea syndrome (OSAHS), Excessive Daytime Sleepiness (EDS), sponsored by Ratchadaphiseksomphot Endowment Fund. Started Nov 2021; status: completed.
02
Drugs
armodafinil
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on TCTR20210218005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210218005.